Too early to say he's incorrect, but I'm hoping he is. We have at least shown that my cancer is very volatile and definitely will progress when untreated, but not yet demonstrated it has developed resistance to the GAC. My neuropathy from the Abraxane continues to build, but if the GAC combo keeps working, I'll do it as long as I can.

It's a fine line of getting into a trial when you're under control with stable disease. I don't want to be declared unable to tolerate more GAC if it's working -- the ideal would be to say I've had as much as I can handle at present, a break for a trial would be good, but I could come back to the GAC if the trial doesn't work. If they write it up as "resistant" or "unable to tolerate" as the "final word" then I might not have the option (by doctor or insurance) to revert.

My onc has proposed a new regimen based on Onivyde (the new liposomal irinotecan) and 5FU, but since the original Folfirinox didn't do much for me, I don't have high hopes for this option.